Back to Search
Start Over
PSMA-based therapeutics for prostate cancer.
- Source :
- Expert Opinion on Pharmacotherapy; Jul2024, Vol. 25 Issue 10, p1405-1419, 15p
- Publication Year :
- 2024
-
Abstract
- Introduction: The prostate cancer (PCa) consists the most frequently diagnosed malignancy of urogenital system in males. Traditionally, treatment of localized PCa was based on surgery or radiotherapy while hormonotherapy was used in more advanced stages. However, the implementation of radiolabels has revolutionized the landscape of prostate cancer. Specifically, prostate-specific membrane antigen (PSMA) has been investigated in different aspects of PCa therapeutic era. Areas covered: A literature review is presented about the implications of PSMA radiolabels on prostate cancer treatment. PSMA tracers were initially used as an imaging technique. Afterwards, PSMA labeled with isotopes presenting cytotoxic abilities, such as lutetium-117 and actinium-225, while reports exist about the use of radioligand immunotherapy. Meanwhile, ongoing trials examine the development of novel radionuclides as well as the evolution of the PSMA-targeted ligands. Expert opinion: Currently, PSMA radioligand treatment of prostate cancer is approved in the metastatic stage of the disease. Meanwhile, a variety of trials exist about its possible role in less advanced stages. However, plenty of parameters should be addressed before these implementations, such as PSMA dosage, dosimetry issues, and its safety profile. A future well-designed study with proper patient selection is mandatory to further explore PSMA radioligand theranostics perspectives. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14656566
- Volume :
- 25
- Issue :
- 10
- Database :
- Complementary Index
- Journal :
- Expert Opinion on Pharmacotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 179108866
- Full Text :
- https://doi.org/10.1080/14656566.2024.2385726